MenACWY Vaccine Pfizer

Menu

Close

HomeAboutAboutMenACWY Vaccine Pfizer in the Routine Immunisation ProgrammeMenACWY Vaccine Pfizer TravelSafetyDosingDosing and AdministrationMenACWY Vaccine Pfizer Dosing and AdministrationMedical InformationVisit the Pfizer Medical Information Africa Website for Healthcare ProfessionalsSubmit a medical question to Pfizer

To report an adverse event, please contact [email protected]
MenACWY Vaccine Pfizer for TravelMenACWY Vaccine Pfizer (meningococcal groups A, C, W-135 and Y conjugate vaccine) is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.1When people travelling are at risk of meningococcal ACWY disease, help protect them with MenACWY Vaccine Pfizer.1,2Meningococcal ACWY vaccination is a requirement for Hajj and Umrah pilgrims3All people travelling to the Kingdom of Saudi Arabia for Hajj or Umrah (including seasonal workers) require proof of Meningococcal ACWY vaccination for entry.3Meningococcal ACWY vaccination is recommended for some people travelling to the ‘meningitis belt’ of sub-Saharan Africa.2Outbreaks of meningococcal meningitis in the meningitis belt can reach epidemic proportions during the dry season (December to June).2Meningococcal ACWY vaccination may also be recommended for long-stay travellers likely to have close contact with the local population, such as:2
  • Backpackers
  • People visiting friends and relatives
  • Aid or health workers
Countries in Africa where vaccination against meningococcal disease is recommended for some travellers:4
Scroll left to view table
Countries
Benin Ethiopia Nigeria
Burkino Faso The Gambia Rwanda
Burundi Ghana Senegal
Cameroon Guinea South Sudan
Central Africa Republic Guinea Bissau Sudan
Chad Kenya Tanzania
Côte d’Ivoire (Ivory Coast) Mali Togo
Democratic Republic of Congo Mauritania Uganda
Eritrea Niger
MenACWY Vaccine in meningococcal ACWY vaccination
  • MenACWY Vaccine Pfizer can be used to help protect a broad age range of people
    • The only meningococcal conjugate ACWY vaccine approved for use from 6 weeks of age, with no upper age limit.*1
  • The first and only ACWY meningococcal conjugate vaccine with antibody persistence evaluated for up to 10 years.1
    • 10 years following MenACWY Vaccine Pfizer vaccination, a proportion of individuals vaccinated at 12-23 months of age and the majority of individuals vaccinated at 2-55 years of age maintained seroprotection (rSBA titres ≥8) for serogroups A, C, W and Y.
  • MenACWY Vaccine Pfizer has a well established safety profile evaluated in clinical studies of over 9,621 individuals.1
  • MenACWY Vaccine Pfizer is supplied with the solvent in a pre-filled syringe, powder in a vial and two needles. 5
  • MenACWY Vaccine Pfizer is certified Halal by the Halal Food Council of Europe. 6

*Note, infants from 6 weeks to less than 6 months of age: two doses, each of 0.5 ml, should be administered with an interval of 2 months between doses. A booster dose should be given at 12 months of age with an interval of at least 2 months after the last MenACWY Vaccine Pfizer vaccination.

References

MenACWY Vaccine Pfizer. Summary of Product Characteristics, Pfizer Ltd. TravelHealthPro. Meningococcal Disease fact sheet. Available here (last accessed April 2022).Travel Health Pro. Hajj and Umrah. Available here (last accessed April 2022).Pulse. Travel Medicine Guide. Available here (updated March 2020, last accessed April 2022).Pfizer Data on File, November 2018 (last accessed April 2022).Pfizer Data on File, November 2016 (last accessed April 2022).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

This site is intended only for Rwanda health care professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2022 Pfizer Inc. All rights reserved.

Disclaimer: The product is not yet licensed by the Board of Health of Rwanda (Rwanda FDA). The product has however obtained prior Board of Health approval for supply to Accord program channels in Rwanda.

You are now leaving Accord Portal to access Pfizer Medical Information Portal  You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.